CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
International Journal of Oncology · 2023
DOI: 10.3892/ijo.2023.5579 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Oncology, 2023. Verfasst von Zhenxing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China.
- School of Pharmacy, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China.
- Department of Anesthesiology, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China.
Zitieren
APA
Wang, Z., Li, L., Chu, C., Wei, X., Liu, Q., Wang, R., Zhang, G., Wu, G., Wang, Y., An, L., & Li, X. (2023). CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells. International Journal of Oncology. https://doi.org/10.3892/ijo.2023.5579
Vancouver
Wang Z, Li L, Chu C, Wei X, Liu Q, Wang R, et al. CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells. International Journal of Oncology. 2023. doi:10.3892/ijo.2023.5579
BibTeX
@article{Wang2023,
author = {Wang, Zhenxing and Li, Lanxin and Chu, Chunhong and Wei, Xiangkai and Liu, Qian and Wang, Rui and Zhang, Guoliang and Wu, Guangyao and Wang, Ying and An, Lei and Li, Xiaodong},
title = {CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells},
journal = {International Journal of Oncology},
year = {2023},
doi = {10.3892/ijo.2023.5579}
}
EUVIMED